Get All Access for $5/mo

Johnson & Johnson acquisitions hit close to $15bn April witnessed a flurry of high-profile acquisitions by Johnson & Johnson, the healthcare behemoth. These strategic moves, amounting to nearly $15 bn, spanned across the medical care and consumer healthcare...

By Brian-Damien Morgan

This story originally appeared on Due

April witnessed a flurry of high-profile acquisitions by Johnson & Johnson, the healthcare behemoth. These strategic moves, amounting to nearly $15 bn, spanned across the medical care and consumer healthcare sectors, further diversifying the company’s portfolio.

The company has announced two major takeover deals involving Ambrx Biopharma, Inc. and Shockwave Medical across April.

Johnson & Johnson’s Spring Acquisitions

The healthcare and pharmacy giant first made a deal with Shockwave at the beginning of this month.

The definitive handover would equate to $335.00 per share in cash and a total company value of $13.1 billion.

Moving for Shockwave expands J&J’s presence in the cardiovascular intervention market for medical science and applications. This is one of the globe’s fastest-growing medical technology markets.

J&J now has a host of new frontiers to explore to make headway in medical science. This also expands the already massive reach the company has over medical technology markets and improves the numbers for the company’s operating and growth margins.

Doug Godshall, President and CEO of Shockwave, said “I am deeply grateful to our team members and colleagues whose efforts have made today’s milestone possible; their accomplishments and passion have been extraordinary. I could not think of a better partner and home than Johnson & Johnson as the Shockwave team prepares to write its next exciting chapter.”

This would only be one of the blockbuster deals the household name would deliver in Spring. The takeover of Ambrx Biopharma, Inc. would allow J&J to foray into more uncharted areas of growth and research.

Antibody-drug conjugates (ADCs) are an existing market, but their consistent growth in development platforms, best-in-class applications, and results are constant.

Ambrx’s joining the J&J fold gives the company a larger foothold in applying and creating ADCs to tackle prostate cancer, which is a massively lucrative medical science market.

J&J took over the leading oncology company for $2.0 billion, which will be officially marked down as a “business combination.”

Biljana Naumovic, Worldwide Vice President, Oncology, Johnson & Johnson Innovative Medicine, said, “ADCs are transforming the solid tumor treatment paradigm by leveraging antibody-antigen interactions to release cytotoxic payload directly to tumor cells. This acquisition underscores our ambition to deliver enhanced, precision biologics to transform the treatment of cancers, including prostate cancer.”

The company also released its 2024 first-quarter earnings report. The report was rosy for J&J, with worldwide sales growing 2.3% to $21.4 bn in the first quarter of the year.

Image: J&J.

The post Johnson & Johnson acquisitions hit close to $15bn appeared first on Due.

Want to be an Entrepreneur Leadership Network contributor? Apply now to join.

Editor's Pick

Business News

Apple Reportedly Isn't Paying OpenAI to Use ChatGPT in iPhones

The next big iPhone update brings ChatGPT directly to Apple devices.

Business News

Sony Pictures Entertainment Purchases Struggling, Cult-Favorite Movie Theater Chain

Alamo Drafthouse originally emerged from bankruptcy in June 2021.


Are Your Business's Local Listings Accurate and Up-to-Date? Here Are the Consequences You Could Face If Not.

Why accurate local listings are crucial for business success — and how to avoid the pitfalls of outdated information.

Growing a Business

He Immigrated to the U.S. and Got a Job at McDonald's — Then His Aversion to Being 'Too Comfortable' Led to a Fast-Growing Company That's Hard to Miss

Voyo Popovic launched his moving and storage company in 2018 — and he's been innovating in the industry ever since.

Money & Finance

Day Traders Often Ignore This One Topic At Their Peril

Boring things — like taxes — can sometimes be highly profitable.


Want to Be More Productive Than Ever? Treat Your Personal Life Like a Work Project.

It pays to emphasize efficiency and efficacy when managing personal time.